Results 201 to 210 of about 1,569,657 (332)
Heart failure in two male patients with late‐onset Fabry mutation (IVS4 + 919G > A)
ESC Heart Failure, Volume 12, Issue 2, Page 1508-1513, April 2025.
Xufei Yang+3 more
wiley +1 more source
Abstract Aims Amyloid cardiomyopathy is caused by the deposition of light chain (AL) or transthyretin amyloid (ATTR) fibrils, that leads to a restrictive cardiomyopathy, often resulting in heart failure (HF) with preserved or reduced ejection fraction.
Robin Willixhofer+25 more
wiley +1 more source
Psychological Interventions for Reducing Distress in Patients with Cardiac Arrhythmias. [PDF]
Särnholm J+4 more
europepmc +1 more source
Abstract Aims Mortality in cardiogenic shock (CS) remains elevated, with the potential for CS causes to impact prognosis and risk stratification. The aim was to investigate in‐hospital prognosis and mortality in CS patients according to aetiology. We also assessed the prognostic accuracy of CardShock and IABP‐SHOCK II scores.
Cosme García‐García+17 more
wiley +1 more source
Dapagliflozin alleviates high‐fat‐induced obesity cardiomyopathy by inhibiting ferroptosis
Abstract Aim: Dapagliflozin (Dapa) is a novel hypoglycaemic agent with multiple cardiovascular protective effects, and it is widely used in treatment of heart failure patients, but whether it can improve obese phenotype of heart failure and its mechanism is still unclear.
Di Chen+7 more
wiley +1 more source
Macrolide Antibiotic Mediated Cardiac Arrhythmias: Emerging Concepts and Clinical Implications. [PDF]
Iqbal F+6 more
europepmc +1 more source
How to demonstrate the clinical implication of prophylactic implantable cardioverter-defibrillator in patients with advanced light chain amyloidosis. [PDF]
Kataoka N, Imamura T.
europepmc +1 more source